Income statement and balance sheet are strong; cash flow is moderate.
Next earnings: 2026-11-02 (AMC), EPS Forecast: $4.36
Upgraded from Sell to Hold in the Mar 2026 quarter: 63.8 → 68.6 (+4.8). This quarter: +3.3.
Change vs previous quarter.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.